In addition to the novel CAR-T therapies offered through our clinical trials program, our care team can provide our patients two FDA-approved therapies:

Kymriah for acute lymphoblastic leukemia or non-Hodgkin lymphoma

Yescarta for non-Hodgkin lymphoma

Please contact Catherine Cheng, catherine_cheng@med.unc.edu, 919-445-4208, to learn more about either of these therapies or to refer a patient.